HTB supplement: 2010 pipeline report
HIV, tuberculosis, and viral hepatitis: drugs, diagnostics, vaccines, immune-based therapies, and preventive technologies in development This year i-Base is partnering with Treatment Action Group (TAG)...
View ArticleAcknowledgments
Authors Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn Kaplan, Erica Lessem, and Tracy Swan Executive Editor Andrea Benzacar Editors Tim...
View ArticleThe tuberculosis vaccine pipeline
Where are we going, where have we been? By Mike Frick Since the 2012 Pipeline Report, results from phase II trials and advances in preclinical development have brought the pipeline for new TB vaccines...
View ArticleThe tuberculosis treatment pipeline
Better than Ever Is Not Good Enough By Erica Lessem Introduction In December 2012, tuberculosis (TB) treatment reached a historic landmark with the first approval by a stringent regulatory authority of...
View ArticleThe tuberculosis diagnostics pipeline
By Colleen Daniels Currently, smear microscopy and mycobacterial culture are the most widely used diagnostic tests, but microscopy, though relatively fast, is too inaccurate—missing over half of cases...
View ArticleLow- and middle-income countries defuse hepatitis C
By Karyn Kaplan As rich countries prepare for a hepatitis C virus (HCV) treatment revolution, people in low- and middle-income countries (LMICs) remain without access to information, prevention tools,...
View ArticleHepatitis C drug development catapults onward
By Tracy Swan Thanks to Jules Levin The pace of, and progress in, hepatitis C virus (HCV) drug development are astonishing. In April 2011, proof-of-concept for safe, effective, peginterferon-free HCV...
View ArticlePreventive technologies, research toward a cure, and immune-based and gene...
By Richard Jefferys Until last year, no product inching through the pipelines covered in this chapter had ever emerged into the marketplace. That changed on July 16, 2012, with the approval in the...
View ArticleRetrofitting for purpose: treatment optimisation
By Polly Clayden Last year’s Pipeline Report saw the addition of a new chapter exploring research into antiretroviral treatment optimisation. This strategy includes the optimisation of approved...
View ArticleThe paediatric antiretroviral pipeline
By Polly Clayden The last Pipeline Report described a bumper year for paediatric antiretroviral approvals. This one reports after a year in which new approvals were fewer and far between. Although the...
View ArticleThe antiretroviral pipeline
By Simon Collins and Tim Horn Introduction The model of pricing newly approved antiretrovirals (ARVs) higher than current drugs is increasingly difficult to sustain, even in a purely commercial...
View ArticleExecutive summary and research policy recommendations
2013 HIV pipeline executive summary The 2013 HIV pipeline comprises adult and pediatric antiretroviral therapy (ART) development and dose-optimization research as well as antiretroviral preventive...
View ArticleSeven ways to speed up the pipeline
By Polly Clayden and Mark Harrington This chapter will discuss how to get the best drugs to the most people as quickly as possible; this requires that the compounds and combination products be:...
View ArticleDedication: Spencer Cox
This report is dedicated to Spencer Cox March 10, 1968–December 18, 2012 Remarks on the Naming of the Spencer Cox Center for Health Melanie Thompson, MD New York City, June 11, 2013 I am so honored to...
View ArticleHTB supplement: 2013 pipeline report online
HIV, hepatItIs C vIrus (HCV), and tuberculosIs (TB) drugs, diagnostics, vaccInes, and prevention technologIes in development
View ArticleAcknowledgments
Authors Polly Clayden, Simon Collins, Colleen daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn Kaplan, Erica Lessem, Lindsay McKenna, and Tracy Swan Executive Editor Andrea...
View ArticleThe tuberculosis vaccines pipeline
Back to basic science By Mike Frick The last year in tuberculosis (TB) vaccine research has demonstrated how setbacks can sometimes produce the potential for unexpected progress. Dominant hypotheses...
View ArticlePlaying catch-up: paediatric tuberculosis treatment pipeline
By Lindsay McKenna Introduction While the pediatric HIV drug pipeline has seen increased activity in recent years, the same cannot be said for pediatric TB. Adult-pediatric approval gaps remain an...
View ArticleTuberculosis drug development hobbles forward
By Erica Lessem Introduction After forty years without new approved drug classes, tuberculosis (TB) treatment has recently advanced with the approval of two new compounds to treat multidrug-resistant...
View ArticleThe tuberculosis diagnostics pipeline
By Colleen Daniels Accurate diagnosis of tuberculosis (TB) is the gateway to treatment and—it is hoped—cure for people with latent TB infection (LTBI) or active TB disease. According to the Stop TB...
View Article
